major cryptocurrencies, Top stories

According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.According to data treasure statistics, excluding central enterprises and state-owned enterprises, among the above three sectors, there are 41 Shanghai local stocks with a market value exceeding 10 billion yuan.In addition, the market value of Zhongwei Company, Weir Shares and UIH Medical all exceeded 100 billion yuan.

Since the beginning of this year, favorable policies for mergers and acquisitions have been frequent. Since the CSRC issued the Opinions on Deepening the Market Reform of Listed Companies' M&A and Restructuring on September 24th, the support of all parties to the M&A and restructuring market has continued to increase, and the M&A and restructuring market has continued to be active.After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).Many stocks have doubled.

It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.According to data treasure statistics, excluding central enterprises and state-owned enterprises, among the above three sectors, there are 41 Shanghai local stocks with a market value exceeding 10 billion yuan.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.